🇯🇵·1d agoIndustry
Zipalertinib Plus Chemotherapy Demonstrates 6-Month Median Progression-Free Survival Benefit in REZILIENT3 Phase 3 Trial in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer
Publisher
O
Otsuka Holdings RSS
Japan
This page provides publisher metadata, and related coverage to support discovery before sending readers to the original article.
Read originalAt a glance
- Publisher
- Otsuka Holdings RSS
- Region
- Japan
- Scope
- Industry
- Published
- September 14, 2026
Publisher context, original article off-platform
This page presents the title, publisher metadata, and related coverage. The publisher did not provide a public summary in this feed. Full-text reading stays on the publisher's original site.
Source route
Continue on taiho.co.jp
Leave the platform to read the original full article on the publisher site.
Source: Otsuka Holdings RSS
Scope: Industry
Related coverage
More related coverage
Nippon Shinyaku News/14h ago
企業活動と医療機関等および患者団体の関係における透明性に関する指針等に基づき、「2025年度 医療機関等への資金提供等の実績」、「2025年度 患者団体への資金提供等の実績」を公開しました
Certara/15h ago
Pharmacometric Analysis of Givinostat to Support Individualized Dosing Recommendations in Pediatric Patients with Duchenne Muscular Dystrophy
Nippon Shinyaku News/18h ago
未来の自分を支える健康習慣へ ニコチンアミドモノヌクレオチドと長命草を配合したサプリメント「NMN」を 2026年9月14日に新発売
WuXi Biologics/16h ago